查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1836843

按产品、成像方式、应用和最终用户分類的临床前成像市场 - 全球预测 2025-2032

Preclinical Imaging Market by Product, Type, Imaging Modality, Applications, End Users - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 192 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年临床前影像市场将成长至 54.9 亿美元，复合年增长率为 5.07%。

主要市场统计数据
基准年2024年 36.9亿美元
预计2025年 38.7亿美元
预测年份：2032年 54.9亿美元
复合年增长率（%） 5.07%

简明介绍临床前影像驱动因素以及仪器、试剂和软体相关人员的策略重点

在技​​术融合、试剂功能扩展以及终端用户需求不断变化等因素的推动下，临床前成像领域正在快速发展。本执行摘要总结了影响临床前研究仪器供应商、试剂开发商、软体供应商和研究买家的当代动态。在这种情况下，领导者必须协调科学研究动态与营运现实，例如实验室工作流程整合、转化研究的监管协调以及日益增长的多模态资料协调需求。

以下章节将重点放在策略曲折点，而非静态指标。读者将获得不同模式变革的分析、2025年关税相关影响对美国供应链的评估，以及阐明谁购买什么、为什么购买的可操作细分洞察。报告旨在为决策者提供结构化的观点，以优先考虑投资、加速商业化并优化伙伴关係关係。本报告重点关注对采购、开发平臺和转换应用的实际影响，为提出有针对性的建议和支持每个结论的严谨方法奠定了基础。

多模态融合、试剂专业化、进阶分析、监管协调和协作模型如何重新定义临床前成像

过去五年，临床前影像技术经历了数次变革，正逐渐成为转化科学的核心组成部分。融合解剖学、功能学和分子学读数的多模态平台正在减少跨平台数据整合的阻力，并缩短临床前决策週期。其次，试剂正变得更加专业化和应用主导，造影剂和示踪剂的设计旨在检测特定的生物通道。

第三，先进的影像处理、人工智慧驱动的分割技术以及定量放射组学技术正在实现更丰富的表型表征。第四，监管预期正转向统一的成像生物标记验证方法，鼓励开发商和监管机构更早开展合作。最后，共同研究模式正在不断发展。学术实验室、合约研究组织 (CRO) 和产业合作伙伴越来越多地采用联盟式研究和共用基础设施，以分摊成本并加速可重复性。总而言之，这些转变正在重新定义整个生态系统的竞争优势和营运韧性。

评估2025年关税对供应链中断和策略采购回应的影响，以因应采购和专案连续性

2025年美国关税调整已在全球临床前成像相关供应链中造成了显着的摩擦，影响了采购计划、零件采购以及进口设备和试剂的成本结构。先前依赖即时进口的供应商面临前置作业时间延长和到岸成本上升的问题，迫使一些供应商重新评估其采购区域和库存政策。为此，一些製造商加快了供应商多元化，并增加了区域组装，以保护客户免受关税波动的影响。

此外，由于采购团队力求在仪器升级与耗材及服务合约相关的营运支出之间取得平衡，客户的资本投资决策也经历了重新排序。关税环境也引发了长期供应协议的谈判，并激发了人们对区域製造伙伴关係的兴趣。重要的是，关税的影响因产品类型而异。高价值、低产量的仪器与对单位成本变化敏感的试剂含量高的耗材相比，需要不同的缓解策略。因此，积极审查筹资策略并与供应链团队合作模拟关税情景的相关人员，能够更好地保持测试的连续性并满足转换专案进度。

将产品类型、系统类型、模式、应用和最终用户优先顺序与策略定位连结的多维细分框架

精细的细分视角揭示了临床前影像市场创新和商业性焦点的集中。试剂包括生物发光成像试剂、萤光成像试剂、MRI造影追踪剂、超音波造影试剂和 X 射线 CT造影试剂等类别。这些频谱驱动着特定于成像模式的工作流程，并决定了耗材的成本概况、保质期和合规性。同时，软体和服务为影像重建、定量分析和资料管理提供了运算基础，通常以云端订阅服务的形式打包。

从类型上看，生态系统的特点是分为多模态和独立成像系统，多模态配置提供整合的工作流程以减少跨平台差异，而独立系统提供集中的功能和较小的资本占用。成像显像模式进一步分为磁粒子成像、磁振造影、微型电脑断层扫描、光学成像、正子断层扫描和单光子发射电脑断层扫描，每种模式在灵敏度、空间解析度和示踪剂相容性方面都有不同的权衡，从而影响研究设计。

心臟病学、药物开发、免疫学/发炎、感染疾病、神经病学和肿瘤学各自都有其独特的终点定义、吞吐量预期和验证需求，推动了技术要求和采购逻辑。学术和研究机构优先考虑灵活性和方法透明度；受託研究机构重视吞吐量、可重复性和监管级文件；製药生物技术公司则强调转化相关性、与临床生物标誌物的数据整合以及供应商课责。整合这些细分层面，为产品定位、商业化策略和研发投资优先顺序提供了一个细緻的架构。

美洲、欧洲、中东和非洲以及亚太地区的商业化动态和差异化的招募管道将塑造打入市场策略

区域动态将显着影响临床前影像的商业化路径和策略重点。在美洲，对转化研究基础设施的投资和密集的生物技术中心网路正在刺激对高性能、受监管服务和高级分析的需求，供应商优先考虑其服务的可靠性和检验。同时，欧洲、中东和非洲是一个多元化的地区，其多样化的监管环境和多样化的医疗保健资金筹措模式需要灵活的商业策略，因此互通性和本地监管指导对于应用至关重要。

在亚太地区，快速提升的研究能力和不断扩展的临床测试活动正在推动对可扩展系统和经济高效耗材的需求，而本地製造伙伴关係和产学研合作则正在加速技术应用。在这些全部区域，人事费用、监管时间表和基础设施成熟度的差异，为多模态平台和独立系统创造了独特的应用曲线，决定了企业优先考虑现场测试、伙伴关係和本地化支援网路。了解这些区域概况对于制定销售策略、客户教育计画和售后服务模式至关重要。

竞争优势源自模组化硬体、试剂准确性、检验的分析以及促进客户维繫的整合服务模式

关键的公司层面洞察揭示了策略选择如何体现在产品系列、市场进入方式和伙伴关係模式中。领先的仪器供应商正在投资模组化架构，以实现增量升级和多模态集成，在保护客户资本的同时实现功能扩展。试剂开发人员正专注于开发高特异性的造影剂和放射性示踪剂，以提高稳定性和批次一致性，并认识到买家信心越来越依赖可重复性和监管文件。

软体和分析公司正透过检验的演算法、透明的效能指标以及与常见实验室资讯管理系统的互通性来脱颖而出。在商业性方面，一些公司正在扩展其服务产品，包括应用支援、成像生物标誌物鑑定和承包测试执行，以吸引寻求单一来源责任制的申办方。硬体供应商、试剂供应商和分析供应商之间的策略伙伴关係正变得越来越普遍，从而实现了配套服务，降低了最终用户的整合风险。最终，那些将技术蓝图与最终用户工作流程和监管期望相结合的公司将获得更牢固的公司间关係和长期合约。

为供应商和买家提供可行的策略重点，以增强供应弹性、模组化整合、监管协调和伙伴关係主导的采用

产业领导者可以透过采取一系列注重弹性、协作和以客户为中心的设计，加速其影响力。首先，重新思考您的供应链架构，纳入双重采购、区域组装和安全库存实践，以减轻贸易中断和零件短缺对您营运的影响。其次，优先考虑模组化产品蓝图和开放整合标准，以减少客户锁定障碍，并实现符合您实验室需求的无缝多模态工作流程。

第三，投资法规和验证支援服务，帮助客户将临床前影像生物标记转化为临床相关的终点。第四，设计商业模式，将资本弹性与以结果为导向的服务等级结合，以适应不同的买家风险状况。第五，与学术中心和合约研究组织 (CRO) 建立伙伴关係，共同开发通讯协定并产生可重复的证据来支持商业性主张。透过实施这些有针对性的措施，组织可以增强竞争优势，保护业务连续性，并加速整个生态系统的技术应用。

我们的混合方法结合了专家访谈、技术基准化分析和三重二手信息，以提供可行的见解。

支撑本分析的调查方法融合了质性专家访谈、技术基准化分析和三角二次研究，以确保坚实的实证基础。包括仪器工程师、试剂化学家、成像科学家和采购负责人在内的领域专家，对特定于模式的权衡取舍和采用驱动因素进行了解读。技术基准测试比较了系统规格、试剂配置和分析能力，以识别趋同和分化的模式。

二级资讯来源包括同行评审文献、临床转换用例、监管指南文件以及製造商发布的技术规范，这些资料被整合在一起，用于检验趋势并确定共识领域和新兴讨论领域。在此过程中，研究结果与从业人员的回馈进行交叉引用，以期为检测设计、采购和商业化提供实际指导。这种混合方法在技术严谨性与市场相关性之间取得平衡，为本简报中提出的可行建议奠定了基础。

综合可行的结论，结合技术融合、营运弹性和监管协调，推动转化临床前影像

最后，临床前成像正处于关键的十字路口，技术成熟度、试剂复杂性和先进分析技术将汇聚一堂，加速转化效应。随着生态系统向整合化、可重复的工作流程转变，透过策略性供应链重新设计、模组化技术采用和强化验证管道进行调整的相关人员将获得巨大的价值。此外，地区差异凸显了製定尊重监管多样性和营运现实的客製化商业化策略的必要性。

随着市场的发展，那些将科学创新与切实可行的商业化实践（例如可扩展的服务交付、伙伴关係主导的方案製定以及清晰的监管合作计划）相结合的组织，将引领技术应用并与最终用户保持长期合作关係。本文提出的见解旨在为此类策略选择提供参考，并为直接采取行动以保障研究的连续性并提升转化成果奠定基础。

目录

第一章：前言

第二章调查方法

第三章执行摘要

第四章 市场概况

第五章 市场洞察

  • 整合人工智慧，实现临床前 MRI 中的自动病变检测和生物标记提取
  • 开发用于小动物模型即时血管评估的高速体积超音波影像系统
  • 采用混合 PET/MRI 平台在肿瘤学研究中同时进行功能与解剖影像
  • 使用造影进行 3D 微型 CT 成像以在囓齿动物模型中进行纵向骨骼密度和血管研究
  • 萤光分子断层扫描技术的进步使得深层组织成像和定量萤光探针分析成为可能
  • 光超音波成像合併超音波动态监测肿瘤氧合及血管变化
  • 影像撷取通讯协定和数据规范化工作流程的标准化，以提高临床前实验室的可重复性

第六章 2025年美国关税的累积影响

第七章 人工智慧的累积影响，2025年

8. 临床前影像市场（按产品）

  • 试剂
    • 生物发光成像试剂
    • 萤光成像试剂
    • MRI造影剂
    • PET放射性追踪剂
    • 超音波造影剂
    • X射线CT造影剂
  • 软体和服务

9. 临床前影像市场（按类型）

  • 多模态系统
  • 独立成像系统

10. 临床前影像市场（依影像方式）

  • 磁粒子成像
  • 磁振造影
  • 微电脑电脑断层扫描
  • 光学成像
  • 正子断层扫描
  • 单光子发射电脑断层扫描

第11章临床前影像市场（按应用）

  • 心臟病学
  • 药物开发
  • 免疫学和炎症
  • 感染疾病
  • 神经病学
  • 肿瘤学

12. 临床前影像市场（依最终使用者）

  • 学术研究机构
  • 合约研究组织
  • 製药和生物技术公司

13. 临床前影像市场（按地区）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

14. 临床前影像市场（按类别）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

15. 临床前影像市场（按国家/地区）

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章竞争格局

  • 2024年市占率分析
  • 2024年FPNV定位矩阵
  • 竞争分析
    • Advanced Molecular Vision, Inc.
    • Agilent Technologies, Inc.
    • Angstrom Advanced Inc.
    • Aspect Imaging Ltd.
    • AXT Pty Ltd
    • Berthold Technologies
    • Bruker Corporation
    • Cubresa, Inc.
    • Euro-BioImaging ERIC
    • FUJIFILM Holdings America Corporation
    • GE HealthCare Technologies Inc.
    • IVIM Technology Corp.
    • KUB Technologies, Inc.
    • LI-COR, Inc.
    • Mediso Ltd.
    • Milabs BV
    • Miltenyi BIoTec GmbH
    • MR Solutions Ltd.
    • Peira bvba
    • PerkinElmer Inc.
    • Revvity, Inc.
    • Scitech Pty Ltd
    • Siemens AG
    • TriFoil Imaging
    • United Imaging Healthcare Co., Ltd.
Product Code: MRR-030EE48515D3

The Preclinical Imaging Market is projected to grow by USD 5.49 billion at a CAGR of 5.07% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 3.69 billion
Estimated Year [2025] USD 3.87 billion
Forecast Year [2032] USD 5.49 billion
CAGR (%) 5.07%

A concise orientation to contemporary preclinical imaging drivers and strategic priorities for instrument, reagent, and software stakeholders

The preclinical imaging landscape is rapidly advancing, driven by technology convergence, expanding reagent capabilities, and evolving end-user demands. This executive summary synthesizes contemporary dynamics affecting instrument vendors, reagent developers, software providers, and institutional buyers engaged in preclinical research. Within this context, leaders must reconcile scientific opportunity with operational realities such as laboratory workflow integration, regulatory alignment for translational studies, and the rising imperative for multimodal data harmonization.

Throughout the following sections, the narrative emphasizes strategic inflection points rather than static metrics. Readers will find an analysis of transformative shifts across modalities, an assessment of tariff-related impacts on the U.S. supply chain in 2025, and actionable segmentation insight that clarifies who buys what, and why. The intent is to furnish decision-makers with a structured perspective for prioritizing investment, accelerating commercialization pathways, and optimizing partnerships. By focusing on practical implications for procurement, development pipelines, and translational adoption, this introduction sets the stage for targeted recommendations and a rigorous methodology that underpins each conclusion.

How multimodal convergence, reagent specialization, advanced analytics, regulatory harmonization, and collaborative models are redefining preclinical imaging

The past five years have seen several transformative shifts that are reshaping preclinical imaging as a core enabler for translational science. First, instrumentation convergence has accelerated; multimodal platforms that combine anatomical, functional, and molecular readouts are reducing the friction of cross-platform data integration, thereby shortening preclinical decision cycles. Second, reagents are becoming more specialized and application-driven, with contrast agents and tracers designed to interrogate discrete biological pathways, which in turn informs more precise study designs and endpoint selection.

Third, software and analytics have moved from optional add-ons to critical differentiators, as advanced image processing, AI-driven segmentation, and quantitative radiomics enable richer phenotypic characterization. Fourth, regulatory expectations are shifting toward harmonized validation approaches for imaging biomarkers, prompting earlier engagement between developers and regulators. Finally, collaboration models are evolving: academic laboratories, CROs, and industry partners increasingly adopt consortium-based studies and shared infrastructure to distribute cost and accelerate reproducibility. Taken together, these shifts are redefining competitive advantage and operational resiliency across the ecosystem.

Assessment of 2025 tariff-induced supply chain disruptions and strategic sourcing responses that influenced procurement and program continuity

The U.S. tariff adjustments implemented in 2025 introduced measurable friction across global supply chains relevant to preclinical imaging, affecting procurement timelines, component sourcing, and cost structures for imported instrumentation and reagents. Vendors that previously relied on just-in-time imports encountered increased lead times and higher landed costs, prompting several to reassess sourcing geographies and inventory policies. In response, some manufacturers accelerated diversification of supplier bases and increased regional assembly to insulate clients from tariff volatility.

Furthermore, customers experienced a re-prioritization of capital expenditure decisions as procurement teams sought to balance equipment upgrades with operational expenditures tied to consumables and service contracts. The tariff environment also catalyzed negotiations on long-term supply agreements and stimulated interest in regional manufacturing partnerships. Importantly, the tariff impact differed across product categories; high-value, low-volume instruments presented different mitigation options than reagent-heavy consumable flows, which are more sensitive to per-unit cost changes. As a result, stakeholders that proactively revised sourcing strategies and engaged supply chain teams to model tariff scenarios were better positioned to maintain study continuity and protect timelines for translational programs.

A multidimensional segmentation framework linking product categories, system types, modalities, applications, and end-user priorities to strategic positioning

A granular segmentation lens clarifies where innovation and commercial focus are concentrated across the preclinical imaging landscape. By product, the market differentiates between Reagents and Software & Services, where Reagents encompass categories such as bioluminescent imaging reagents, fluorescent imaging reagents, MRI contrasting reagents, PET radioactive tracers, ultrasound contrasting reagents, and X-ray CT contrasting reagents; this spectrum drives modality-specific workflows and dictates consumable cost profiles, shelf-life considerations, and regulatory handling. In parallel, Software & Services deliver the computational backbone for image reconstruction, quantitative analysis, and data management, increasingly packaged as cloud-enabled, subscription-based services.

By type, the ecosystem is characterized by a split between multimodal systems and standalone imaging systems, with multimodal configurations offering integrated workflows that reduce cross-platform variability while standalone systems provide focused capability and lower capital footprints. Imaging modality further stratifies the landscape into magnetic particle imaging, magnetic resonance imaging, micro-computed tomography, optical imaging, positron emission tomography, and single-photon emission computed tomography, each modality presenting distinct sensitivity, spatial resolution, and tracer compatibility trade-offs that shape study design.

Applications drive technical requirements and purchasing logic, as cardiology, drug development, immunology & inflammation, infectious diseases, neurology, and oncology each impose unique endpoint definitions, throughput expectations, and validation needs. End users consolidate the demand side; academic and research institutes prioritize flexibility and methodological transparency, contract research organizations emphasize throughput, reproducibility, and regulatory-grade documentation, and pharmaceutical and biotechnology companies focus on translational relevance, data integration with clinical biomarkers, and vendor accountability. Integrating these segmentation layers yields a nuanced framework for product positioning, commercialization strategy, and prioritization of R&D investments.

Regional commercialization dynamics and differentiated adoption pathways across the Americas, Europe Middle East & Africa, and Asia-Pacific that shape go-to-market strategy

Regional dynamics materially influence commercialization pathways and strategic priorities across preclinical imaging. In the Americas, investment in translational research infrastructure and a dense network of biotechnology hubs stimulates demand for high-throughput, regulatory-aligned services and advanced analytics, prompting vendors to emphasize service reliability and validation. Meanwhile, Europe, Middle East & Africa presents a heterogeneous landscape where regulatory diversity and varied healthcare funding models necessitate flexible commercial strategies; here, interoperability and local regulatory counsel are decisive factors for adoption.

In the Asia-Pacific region, rapid growth in research capacity, combined with expanding clinical trial activity, is driving appetite for scalable systems and cost-effective consumables, while local manufacturing partnerships and academic-industry collaborations are accelerating technology diffusion. Across these regions, differences in labor costs, regulatory timelines, and infrastructure maturity create distinct adoption curves for multimodal platforms versus standalone systems, and they shape where companies prioritize field trials, partnerships, and localized support networks. Understanding these regional contours is essential for aligning distribution strategies, customer education programs, and after-sales service models.

Competitive advantages derived from modular hardware, reagent precision, validated analytics, and integrated service models that drive customer retention

Key company-level insights reveal how strategic choices manifest across product portfolios, go-to-market approaches, and partnership models. Leading instrumentation providers are investing in modular architectures that allow incremental upgrades and multimodal integration, thereby protecting customer capital while enabling feature expansion. Reagent developers are concentrating on high-specificity contrast agents and radiotracers with improved stability and batch consistency, recognizing that reproducibility and regulatory documentation increasingly determine purchaser confidence.

Software and analytics firms are differentiating through validated algorithms, transparent performance metrics, and interoperability with common laboratory information management systems. On the commercial front, several companies are expanding service offerings to include application support, imaging biomarker qualification, and turnkey study execution, which appeals to sponsors seeking single-source accountability. Strategic partnerships between hardware vendors, reagent suppliers, and analytics providers are becoming more prevalent, enabling bundled offerings that reduce integration risk for end users. Ultimately, companies that align technical roadmaps with end-user workflows and regulatory expectations will secure stronger enterprise relationships and longer-term contracts.

Practical strategic priorities for vendors and purchasers to strengthen supply resilience, modular integration, regulatory alignment, and partnership-driven adoption

Industry leaders can accelerate impact by adopting a set of pragmatic, high-return actions focused on resilience, collaboration, and customer-centric design. First, reassess supply chain architecture to incorporate dual sourcing, regional assembly, and safety stock policies that mitigate the operational effects of trade disruptions and component scarcity. Second, prioritize modular product roadmaps and open integration standards to reduce customer lock-in barriers and enable seamless multimodal workflows that align with laboratory needs.

Third, invest in regulatory and validation support services that help customers translate preclinical imaging biomarkers into clinically relevant endpoints; such services increase perceived vendor value and shorten adoption cycles. Fourth, design commercial models that combine capital flexibility with outcome-oriented service tiers, thereby addressing diverse buyer risk profiles. Fifth, cultivate partnerships with academic centers and CROs to co-develop protocols and generate reproducibility evidence that underpins commercial claims. By implementing these targeted measures, organizations can strengthen competitive differentiation, protect operational continuity, and accelerate technology adoption across the ecosystem.

A mixed-methods approach combining expert interviews, technology benchmarking, and triangulated secondary sources to derive practical and validated insights

The research methodology underpinning this analysis blends qualitative expert interviews, technology benchmarking, and triangulated secondary research to ensure a robust evidentiary foundation. Subject-matter experts including instrument engineers, reagent chemists, imaging scientists, and procurement leads informed the interpretation of modality-specific trade-offs and adoption drivers. Technology benchmarking compared system specifications, reagent profiles, and analytical capabilities to identify patterns of convergence and differentiation.

Secondary sources included peer-reviewed literature, clinical translation case studies, regulatory guidance documents, and publicly available technical specifications from manufacturers, which were synthesized to validate trends and to identify areas of consensus versus emerging debate. Throughout the process, findings were cross-checked against practitioner feedback to surface practical implications for study design, procurement, and commercialization. This mixed-methods approach balances technical rigor with market relevance and supports the actionable recommendations provided in this summary.

Synthesizing actionable conclusions that connect technological convergence, operational resilience, and regulatory alignment to advance translational preclinical imaging

In closing, preclinical imaging stands at a pivotal juncture where technological maturity, reagent sophistication, and advanced analytics converge to accelerate translational impact. Stakeholders who adapt through strategic supply chain redesign, modular technology adoption, and strengthened validation pathways will capture disproportionate value as the ecosystem shifts toward integrated, reproducible workflows. Moreover, regional differences emphasize the need for tailored commercialization strategies that respect regulatory diversity and operational realities.

As the market evolves, the organizations that integrate scientific innovation with pragmatic commercialization practices-such as scalable service offerings, partnership-driven protocol development, and clear regulatory engagement plans-will lead adoption and sustain long-term relationships with end users. The insights presented here are designed to inform those strategic choices and to provide a foundation for immediate actions that protect study continuity and enhance translational outcomes.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Integration of artificial intelligence for automated lesion detection and biomarker extraction in preclinical MRI
  • 5.2. Development of high-speed volumetric ultrasound imaging systems for real-time vascular assessment in small animal models
  • 5.3. Adoption of hybrid PET/MRI platforms for simultaneous functional and anatomical imaging in oncology research
  • 5.4. Implementation of 3D micro-CT imaging with contrast agents for longitudinal bone density and vascular studies in rodent models
  • 5.5. Advancements in fluorescence molecular tomography enabling deep tissue imaging and quantitative fluorescent probe analysis
  • 5.6. Use of photoacoustic imaging combined with ultrasound to monitor tumor oxygenation and vascular changes dynamically
  • 5.7. Standardization of image acquisition protocols and data normalization workflows to enhance reproducibility across preclinical sites

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Preclinical Imaging Market, by Product

  • 8.1. Reagents
    • 8.1.1. Bioluminescent Imaging Reagents
    • 8.1.2. Fluorescent Imaging Reagents
    • 8.1.3. MRI Contrasting Reagents
    • 8.1.4. PET Radioactive Tracers
    • 8.1.5. Ultrasound Contrasting Reagents
    • 8.1.6. X-ray CT Contrasting Reagents
  • 8.2. Software & Services

9. Preclinical Imaging Market, by Type

  • 9.1. Multimodal Systems
  • 9.2. Standalone Imaging Systems

10. Preclinical Imaging Market, by Imaging Modality

  • 10.1. Magnetic Particle Imaging
  • 10.2. Magnetic Resonance Imaging
  • 10.3. Micro-Computed Tomography
  • 10.4. Optical Imaging
  • 10.5. Positron Emission Tomography
  • 10.6. Single-Photon Emission Computed Tomography

11. Preclinical Imaging Market, by Applications

  • 11.1. Cardiology
  • 11.2. Drug Development
  • 11.3. Immunology & Inflammation
  • 11.4. Infectious Diseases
  • 11.5. Neurology
  • 11.6. Oncology

12. Preclinical Imaging Market, by End Users

  • 12.1. Academic & Research Institutes
  • 12.2. Contract Research Organizations
  • 12.3. Pharmaceutical & Biotechnology Companies

13. Preclinical Imaging Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Preclinical Imaging Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Preclinical Imaging Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. Advanced Molecular Vision, Inc.
    • 16.3.2. Agilent Technologies, Inc.
    • 16.3.3. Angstrom Advanced Inc.
    • 16.3.4. Aspect Imaging Ltd.
    • 16.3.5. AXT Pty Ltd
    • 16.3.6. Berthold Technologies
    • 16.3.7. Bruker Corporation
    • 16.3.8. Cubresa, Inc.
    • 16.3.9. Euro-BioImaging ERIC
    • 16.3.10. FUJIFILM Holdings America Corporation
    • 16.3.11. GE HealthCare Technologies Inc.
    • 16.3.12. IVIM Technology Corp.
    • 16.3.13. KUB Technologies, Inc.
    • 16.3.14. LI-COR, Inc.
    • 16.3.15. Mediso Ltd.
    • 16.3.16. Milabs B.V.
    • 16.3.17. Miltenyi Biotec GmbH
    • 16.3.18. MR Solutions Ltd.
    • 16.3.19. Peira bvba
    • 16.3.20. PerkinElmer Inc.
    • 16.3.21. Revvity, Inc.
    • 16.3.22. Scitech Pty Ltd
    • 16.3.23. Siemens AG
    • 16.3.24. TriFoil Imaging
    • 16.3.25. United Imaging Healthcare Co., Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL PRECLINICAL IMAGING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY PRODUCT, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY PRODUCT, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY TYPE, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY IMAGING MODALITY, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY IMAGING MODALITY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY APPLICATIONS, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY APPLICATIONS, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY END USERS, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY END USERS, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AMERICAS PRECLINICAL IMAGING MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. NORTH AMERICA PRECLINICAL IMAGING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. LATIN AMERICA PRECLINICAL IMAGING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA PRECLINICAL IMAGING MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. EUROPE PRECLINICAL IMAGING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. MIDDLE EAST PRECLINICAL IMAGING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AFRICA PRECLINICAL IMAGING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC PRECLINICAL IMAGING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASEAN PRECLINICAL IMAGING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GCC PRECLINICAL IMAGING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION PRECLINICAL IMAGING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BRICS PRECLINICAL IMAGING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. G7 PRECLINICAL IMAGING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NATO PRECLINICAL IMAGING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. PRECLINICAL IMAGING MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. PRECLINICAL IMAGING MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. PRECLINICAL IMAGING MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL PRECLINICAL IMAGING MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL PRECLINICAL IMAGING MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY REAGENTS, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY REAGENTS, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY REAGENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY REAGENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY REAGENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY REAGENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY REAGENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY REAGENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY BIOLUMINESCENT IMAGING REAGENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY BIOLUMINESCENT IMAGING REAGENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY BIOLUMINESCENT IMAGING REAGENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY BIOLUMINESCENT IMAGING REAGENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY BIOLUMINESCENT IMAGING REAGENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY BIOLUMINESCENT IMAGING REAGENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY FLUORESCENT IMAGING REAGENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY FLUORESCENT IMAGING REAGENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY FLUORESCENT IMAGING REAGENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY FLUORESCENT IMAGING REAGENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY FLUORESCENT IMAGING REAGENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY FLUORESCENT IMAGING REAGENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY MRI CONTRASTING REAGENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY MRI CONTRASTING REAGENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY MRI CONTRASTING REAGENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY MRI CONTRASTING REAGENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY MRI CONTRASTING REAGENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY MRI CONTRASTING REAGENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY PET RADIOACTIVE TRACERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY PET RADIOACTIVE TRACERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY PET RADIOACTIVE TRACERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY PET RADIOACTIVE TRACERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY PET RADIOACTIVE TRACERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY PET RADIOACTIVE TRACERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY ULTRASOUND CONTRASTING REAGENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY ULTRASOUND CONTRASTING REAGENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY ULTRASOUND CONTRASTING REAGENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY ULTRASOUND CONTRASTING REAGENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY ULTRASOUND CONTRASTING REAGENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY ULTRASOUND CONTRASTING REAGENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY X-RAY CT CONTRASTING REAGENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY X-RAY CT CONTRASTING REAGENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY X-RAY CT CONTRASTING REAGENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY X-RAY CT CONTRASTING REAGENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY X-RAY CT CONTRASTING REAGENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY X-RAY CT CONTRASTING REAGENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY SOFTWARE & SERVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY SOFTWARE & SERVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY SOFTWARE & SERVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY SOFTWARE & SERVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY SOFTWARE & SERVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY SOFTWARE & SERVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY MULTIMODAL SYSTEMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY MULTIMODAL SYSTEMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY MULTIMODAL SYSTEMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY MULTIMODAL SYSTEMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY MULTIMODAL SYSTEMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY MULTIMODAL SYSTEMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY STANDALONE IMAGING SYSTEMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY STANDALONE IMAGING SYSTEMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY STANDALONE IMAGING SYSTEMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY STANDALONE IMAGING SYSTEMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY STANDALONE IMAGING SYSTEMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY STANDALONE IMAGING SYSTEMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY IMAGING MODALITY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY IMAGING MODALITY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY MAGNETIC PARTICLE IMAGING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY MAGNETIC PARTICLE IMAGING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY MAGNETIC PARTICLE IMAGING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY MAGNETIC PARTICLE IMAGING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY MAGNETIC PARTICLE IMAGING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY MAGNETIC PARTICLE IMAGING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY MICRO-COMPUTED TOMOGRAPHY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY MICRO-COMPUTED TOMOGRAPHY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY MICRO-COMPUTED TOMOGRAPHY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY MICRO-COMPUTED TOMOGRAPHY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY MICRO-COMPUTED TOMOGRAPHY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY MICRO-COMPUTED TOMOGRAPHY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY OPTICAL IMAGING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY OPTICAL IMAGING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY OPTICAL IMAGING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY OPTICAL IMAGING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY OPTICAL IMAGING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY OPTICAL IMAGING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY SINGLE-PHOTON EMISSION COMPUTED TOMOGRAPHY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY SINGLE-PHOTON EMISSION COMPUTED TOMOGRAPHY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY SINGLE-PHOTON EMISSION COMPUTED TOMOGRAPHY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY SINGLE-PHOTON EMISSION COMPUTED TOMOGRAPHY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY SINGLE-PHOTON EMISSION COMPUTED TOMOGRAPHY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY SINGLE-PHOTON EMISSION COMPUTED TOMOGRAPHY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY APPLICATIONS, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY APPLICATIONS, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY CARDIOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY CARDIOLOGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY CARDIOLOGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY CARDIOLOGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY CARDIOLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY CARDIOLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY DRUG DEVELOPMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY DRUG DEVELOPMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY DRUG DEVELOPMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY DRUG DEVELOPMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY DRUG DEVELOPMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY DRUG DEVELOPMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY IMMUNOLOGY & INFLAMMATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY IMMUNOLOGY & INFLAMMATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY IMMUNOLOGY & INFLAMMATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY IMMUNOLOGY & INFLAMMATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY IMMUNOLOGY & INFLAMMATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY IMMUNOLOGY & INFLAMMATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY INFECTIOUS DISEASES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY INFECTIOUS DISEASES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY NEUROLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY NEUROLOGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY NEUROLOGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY NEUROLOGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY NEUROLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY NEUROLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY ONCOLOGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY ONCOLOGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY END USERS, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY END USERS, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 169. AMERICAS PRECLINICAL IMAGING MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 170. AMERICAS PRECLINICAL IMAGING MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 171. AMERICAS PRECLINICAL IMAGING MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 172. AMERICAS PRECLINICAL IMAGING MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 173. AMERICAS PRECLINICAL IMAGING MARKET SIZE, BY REAGENTS, 2018-2024 (USD MILLION)
  • TABLE 174. AMERICAS PRECLINICAL IMAGING MARKET SIZE, BY REAGENTS, 2025-2032 (USD MILLION)
  • TABLE 175. AMERICAS PRECLINICAL IMAGING MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 176. AMERICAS PRECLINICAL IMAGING MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 177. AMERICAS PRECLINICAL IMAGING MARKET SIZE, BY IMAGING MODALITY, 2018-2024 (USD MILLION)
  • TABLE 178. AMERICAS PRECLINICAL IMAGING MARKET SIZE, BY IMAGING MODALITY, 2025-2032 (USD MILLION)
  • TABLE 179. AMERICAS PRECLINICAL IMAGING MARKET SIZE, BY APPLICATIONS, 2018-2024 (USD MILLION)
  • TABLE 180. AMERICAS PRECLINICAL IMAGING MARKET SIZE, BY APPLICATIONS, 2025-2032 (USD MILLION)
  • TABLE 181. AMERICAS PRECLINICAL IMAGING MARKET SIZE, BY END USERS, 2018-2024 (USD MILLION)
  • TABLE 182. AMERICAS PRECLINICAL IMAGING MARKET SIZE, BY END USERS, 2025-2032 (USD MILLION)
  • TABLE 183. NORTH AMERICA PRECLINICAL IMAGING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 184. NORTH AMERICA PRECLINICAL IMAGING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 185. NORTH AMERICA PRECLINICAL IMAGING MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 186. NORTH AMERICA PRECLINICAL IMAGING MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 187. NORTH AMERICA PRECLINICAL IMAGING MARKET SIZE, BY REAGENTS, 2018-2024 (USD MILLION)
  • TABLE 188. NORTH AMERICA PRECLINICAL IMAGING MARKET SIZE, BY REAGENTS, 2025-2032 (USD MILLION)
  • TABLE 189. NORTH AMERICA PRECLINICAL IMAGING MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 190. NORTH AMERICA PRECLINICAL IMAGING MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 191. NORTH AMERICA PRECLINICAL IMAGING MARKET SIZE, BY IMAGING MODALITY, 2018-2024 (USD MILLION)
  • TABLE 192. NORTH AMERICA PRECLINICAL IMAGING MARKET SIZE, BY IMAGING MODALITY, 2025-2032 (USD MILLION)
  • TABLE 193. NORTH AMERICA PRECLINICAL IMAGING MARKET SIZE, BY APPLICATIONS, 2018-2024 (USD MILLION)
  • TABLE 194. NORTH AMERICA PRECLINICAL IMAGING MARKET SIZE, BY APPLICATIONS, 2025-2032 (USD MILLION)
  • TABLE 195. NORTH AMERICA PRECLINICAL IMAGING MARKET SIZE, BY END USERS, 2018-2024 (USD MILLION)
  • TABLE 196. NORTH AMERICA PRECLINICAL IMAGING MARKET SIZE, BY END USERS, 2025-2032 (USD MILLION)
  • TABLE 197. LATIN AMERICA PRECLINICAL IMAGING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 198. LATIN AMERICA PRECLINICAL IMAGING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 199. LATIN AMERICA PRECLINICAL IMAGING MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 200. LATIN AMERICA PRECLINICAL IMAGING MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 201. LATIN AMERICA PRECLINICAL IMAGING MARKET SIZE, BY REAGENTS, 2018-2024 (USD MILLION)
  • TABLE 202. LATIN AMERICA PRECLINICAL IMAGING MARKET SIZE, BY REAGENTS, 2025-2032 (USD MILLION)
  • TABLE 203. LATIN AMERICA PRECLINICAL IMAGING MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 204. LATIN AMERICA PRECLINICAL IMAGING MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 205. LATIN AMERICA PRECLINICAL IMAGING MARKET SIZE, BY IMAGING MODALITY, 2018-2024 (USD MILLION)
  • TABLE 206. LATIN AMERICA PRECLINICAL IMAGING MARKET SIZE, BY IMAGING MODALITY, 2025-2032 (USD MILLION)
  • TABLE 207. LATIN AMERICA PRECLINICAL IMAGING MARKET SIZE, BY APPLICATIONS, 2018-2024 (USD MILLION)
  • TABLE 208. LATIN AMERICA PRECLINICAL IMAGING MARKET SIZE, BY APPLICATIONS, 2025-2032 (USD MILLION)
  • TABLE 209. LATIN AMERICA PRECLINICAL IMAGING MARKET SIZE, BY END USERS, 2018-2024 (USD MILLION)
  • TABLE 210. LATIN AMERICA PRECLINICAL IMAGING MARKET SIZE, BY END USERS, 2025-2032 (USD MILLION)
  • TABLE 211. EUROPE, MIDDLE EAST & AFRICA PRECLINICAL IMAGING MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 212. EUROPE, MIDDLE EAST & AFRICA PRECLINICAL IMAGING MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 213. EUROPE, MIDDLE EAST & AFRICA PRECLINICAL IMAGING MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 214. EUROPE, MIDDLE EAST & AFRICA PRECLINICAL IMAGING MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 215. EUROPE, MIDDLE EAST & AFRICA PRECLINICAL IMAGING MARKET SIZE, BY REAGENTS, 2018-2024 (USD MILLION)
  • TABLE 216. EUROPE, MIDDLE EAST & AFRICA PRECLINICAL IMAGING MARKET SIZE, BY REAGENTS, 2025-2032 (USD MILLION)
  • TABLE 217. EUROPE, MIDDLE EAST & AFRICA PRECLINICAL IMAGING MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 218. EUROPE, MIDDLE EAST & AFRICA PRECLINICAL IMAGING MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 219. EUROPE, MIDDLE EAST & AFRICA PRECLINICAL IMAGING MARKET SIZE, BY IMAGING MODALITY, 2018-2024 (USD MILLION)
  • TABLE 220. EUROPE, MIDDLE EAST & AFRICA PRECLINICAL IMAGING MARKET SIZE, BY IMAGING MODALITY, 2025-2032 (USD MILLION)
  • TABLE 221. EUROPE, MIDDLE EAST & AFRICA PRECLINICAL IMAGING MARKET SIZE, BY APPLICATIONS, 2018-2024 (USD MILLION)
  • TABLE 222. EUROPE, MIDDLE EAST & AFRICA PRECLINICAL IMAGING MARKET SIZE, BY APPLICATIONS, 2025-2032 (USD MILLION)
  • TABLE 223. EUROPE, MIDDLE EAST & AFRICA PRECLINICAL IMAGING MARKET SIZE, BY END USERS, 2018-2024 (USD MILLION)
  • TABLE 224. EUROPE, MIDDLE EAST & AFRICA PRECLINICAL IMAGING MARKET SIZE, BY END USERS, 2025-2032 (USD MILLION)
  • TABLE 225. EUROPE PRECLINICAL IMAGING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 226. EUROPE PRECLINICAL IMAGING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 227. EUROPE PRECLINICAL IMAGING MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 228. EUROPE PRECLINICAL IMAGING MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 229. EUROPE PRECLINICAL IMAGING MARKET SIZE, BY REAGENTS, 2018-2024 (USD MILLION)
  • TABLE 230. EUROPE PRECLINICAL IMAGING MARKET SIZE, BY REAGENTS, 2025-2032 (USD MILLION)
  • TABLE 231. EUROPE PRECLINICAL IMAGING MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 232. EUROPE PRECLINICAL IMAGING MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 233. EUROPE PRECLINICAL IMAGING MARKET SIZE, BY IMAGING MODALITY, 2018-2024 (USD MILLION)
  • TABLE 234. EUROPE PRECLINICAL IMAGING MARKET SIZE, BY IMAGING MODALITY, 2025-2032 (USD MILLION)
  • TABLE 235. EUROPE PRECLINICAL IMAGING MARKET SIZE, BY APPLICATIONS, 2018-2024 (USD MILLION)
  • TABLE 236. EUROPE PRECLINICAL IMAGING MARKET SIZE, BY APPLICATIONS, 2025-2032 (USD MILLION)
  • TABLE 237. EUROPE PRECLINICAL IMAGING MARKET SIZE, BY END USERS, 2018-2024 (USD MILLION)
  • TABLE 238. EUROPE PRECLINICAL IMAGING MARKET SIZE, BY END USERS, 2025-2032 (USD MILLION)
  • TABLE 239. MIDDLE EAST PRECLINICAL IMAGING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 240. MIDDLE EAST PRECLINICAL IMAGING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 241. MIDDLE EAST PRECLINICAL IMAGING MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 242. MIDDLE EAST PRECLINICAL IMAGING MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 243. MIDDLE EAST PRECLINICAL IMAGING MARKET SIZE, BY REAGENTS, 2018-2024 (USD MILLION)
  • TABLE 244. MIDDLE EAST PRECLINICAL IMAGING MARKET SIZE, BY REAGENTS, 2025-2032 (USD MILLION)
  • TABLE 245. MIDDLE EAST PRECLINICAL IMAGING MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 246. MIDDLE EAST PRECLINICAL IMAGING MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 247. MIDDLE EAST PRECLINICAL IMAGING MARKET SIZE, BY IMAGING MODALITY, 2018-2024 (USD MILLION)
  • TABLE 248. MIDDLE EAST PRECLINICAL IMAGING MARKET SIZE, BY IMAGING MODALITY, 2025-2032 (USD MILLION)
  • TABLE 249. MIDDLE EAST PRECLINICAL IMAGING MARKET SIZE, BY APPLICATIONS, 2018-2024 (USD MILLION)
  • TABLE 250. MIDDLE EAST PRECLINICAL IMAGING MARKET SIZE, BY APPLICATIONS, 2025-2032 (USD MILLION)
  • TABLE 251. MIDDLE EAST PRECLINICAL IMAGING MARKET SIZE, BY END USERS, 2018-2024 (USD MILLION)
  • TABLE 252. MIDDLE EAST PRECLINICAL IMAGING MARKET SIZE, BY END USERS, 2025-2032 (USD MILLION)
  • TABLE 253. AFRICA PRECLINICAL IMAGING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 254. AFRICA PRECLINICAL IMAGING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 255. AFRICA PRECLINICAL IMAGING MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 256. AFRICA PRECLINICAL IMAGING MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 257. AFRICA PRECLINICAL IMAGING MARKET SIZE, BY REAGENTS, 2018-2024 (USD MILLION)
  • TABLE 258. AFRICA PRECLINICAL IMAGING MARKET SIZE, BY REAGENTS, 2025-2032 (USD MILLION)
  • TABLE 259. AFRICA PRECLINICAL IMAGING MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 260. AFRICA PRECLINICAL IMAGING MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 261. AFRICA PRECLINICAL IMAGING MARKET SIZE, BY IMAGING MODALITY, 2018-2024 (USD MILLION)
  • TABLE 262. AFRICA PRECLINICAL IMAGING MARKET SIZE, BY IMAGING MODALITY, 2025-2032 (USD MILLION)
  • TABLE 263. AFRICA PRECLINICAL IMAGING MARKET SIZE, BY APPLICATIONS, 2018-2024 (USD MILLION)
  • TABLE 264. AFRICA PRECLINICAL IMAGING MARKET SIZE, BY APPLICATIONS, 2025-2032 (USD MILLION)
  • TABLE 265. AFRICA PRECLINICAL IMAGING MARKET SIZE, BY END USERS, 2018-2024 (USD MILLION)
  • TABLE 266. AFRICA PRECLINICAL IMAGING MARKET SIZE, BY END USERS, 2025-2032 (USD MILLION)
  • TABLE 267. ASIA-PACIFIC PRECLINICAL IMAGING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 268. ASIA-PACIFIC PRECLINICAL IMAGING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 269. ASIA-PACIFIC PRECLINICAL IMAGING MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 270. ASIA-PACIFIC PRECLINICAL IMAGING MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 271. ASIA-PACIFIC PRECLINICAL IMAGING MARKET SIZE, BY REAGENTS, 2018-2024 (USD MILLION)
  • TABLE 272. ASIA-PACIFIC PRECLINICAL IMAGING MARKET SIZE, BY REAGENTS, 2025-2032 (USD MILLION)
  • TABLE 273. ASIA-PACIFIC PRECLINICAL IMAGING MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 274. ASIA-PACIFIC PRECLINICAL IMAGING MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 275. ASIA-PACIFIC PRECLINICAL IMAGING MARKET SIZE, BY IMAGING MODALITY, 2018-2024 (USD MILLION)
  • TABLE 276. ASIA-PACIFIC PRECLINICAL IMAGING MARKET SIZE, BY IMAGING MODALITY, 2025-2032 (USD MILLION)
  • TABLE 277. ASIA-PACIFIC PRECLINICAL IMAGING MARKET SIZE, BY APPLICATIONS, 2018-2024 (USD MILLION)
  • TABLE 278. ASIA-PACIFIC PRECLINICAL IMAGING MARKET SIZE, BY APPLICATIONS, 2025-2032 (USD MILLION)
  • TABLE 279. ASIA-PACIFIC PRECLINICAL IMAGING MARKET SIZE, BY END USERS, 2018-2024 (USD MILLION)
  • TABLE 280. ASIA-PACIFIC PRECLINICAL IMAGING MARKET SIZE, BY END USERS, 2025-2032 (USD MILLION)
  • TABLE 281. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 282. GLOBAL PRECLINICAL IMAGING MARKET SIZE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 283. ASEAN PRECLINICAL IMAGING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 284. ASEAN PRECLINICAL IMAGING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 285. ASEAN PRECLINICAL IMAGING MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 286. ASEAN PRECLINICAL IMAGING MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 287. ASEAN PRECLINICAL IMAGING MARKET SIZE, BY REAGENTS, 2018-2024 (USD MILLION)
  • TABLE 288. ASEAN PRECLINICAL IMAGING MARKET SIZE, BY REAGENTS, 2025-2032 (USD MILLION)
  • TABLE 289. ASEAN PRECLINICAL IMAGING MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 290. ASEAN PRECLINICAL IMAGING MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 291. ASEAN PRECLINICAL IMAGING MARKET SIZE, BY IMAGING MODALITY, 2018-2024 (USD MILLION)
  • TABLE 292. ASEAN PRECLINICAL IMAGING MARKET SIZE, BY IMAGING MODALITY, 2025-2032 (USD MILLION)
  • TABLE 293. ASEAN PRECLINICAL IMAGING MARKET SIZE, BY APPLICATIONS, 2018-2024 (USD MILLION)
  • TABLE 294. ASEAN PRECLINICAL IMAGING MARKET SIZE, BY APPLICATIONS, 2025-2032 (USD MILLION)
  • TABLE 295. ASEAN PRECLINICAL IMAGING MARKET SIZE, BY END USERS, 2018-2024 (USD MILLION)
  • TABLE 296. ASEAN PRECLINICAL IMAGING MARKET SIZE, BY END USERS, 2025-2032 (USD MILLION)
  • TABLE 297. GCC PRECLINICAL IMAGING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 298. GCC PRECLINICAL IMAGING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 299. GCC PRECLINICAL IMAGING MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 300. GCC PRECLINICAL IMAGING MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 301. GCC PRECLINICAL IMAGING MARKET SIZE, BY REAGENTS, 2018-2024 (USD MILLION)
  • TABLE 302. GCC PRECLINICAL IMAGING MARKET SIZE, BY REAGENTS, 2025-2032 (USD MILLION)
  • TABLE 303. GCC PRECLINICAL IMAGING MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 304. GCC PRECLINICAL IMAGING MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 305. GCC PRECLINICAL IMAGING MARKET SIZE, BY IMAGING MODALITY, 2018-2024 (USD MILLION)
  • TABLE 306. GCC PRECLINICAL IMAGING MARKET SIZE, BY IMAGING MODALITY, 2025-2032 (USD MILLION)
  • TABLE 307. GCC PRECLINICAL IMAGING MARKET SIZE, BY APPLICATIONS, 2018-2024 (USD MILLION)
  • TABLE 308. GCC PRECLINICAL IMAGING MARKET SIZE, BY APPLICATIONS, 2025-2032 (USD MILLION)
  • TABLE 309. GCC PRECLINICAL IMAGING MARKET SIZE, BY END USERS, 2018-2024 (USD MILLION)
  • TABLE 310. GCC PRECLINICAL IMAGING MARKET SIZE, BY END USERS, 2025-2032 (USD MILLION)
  • TABLE 311. EUROPEAN UNION PRECLINICAL IMAGING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 312. EUROPEAN UNION PRECLINICAL IMAGING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 313. EUROPEAN UNION PRECLINICAL IMAGING MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 314. EUROPEAN UNION PRECLINICAL IMAGING MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 315. EUROPEAN UNION PRECLINICAL IMAGING MARKET SIZE, BY REAGENTS, 2018-2024 (USD MILLION)
  • TABLE 316. EUROPEAN UNION PRECLINICAL IMAGING MARKET SIZE, BY REAGENTS, 2025-2032 (USD MILLION)
  • TABLE 317. EUROPEAN UNION PRECLINICAL IMAGING MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 318. EUROPEAN UNION PRECLINICAL IMAGING MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 319. EUROPEAN UNION PRECLINICAL IMAGING MARKET SIZE, BY IMAGING MODALITY, 2018-2024 (USD MILLION)
  • TABLE 320. EUROPEAN UNION PRECLINICAL IMAGING MARKET SIZE, BY IMAG